concert pills
Living With CFNews & EventsResearchTreatments

Vertex Acquires Concert’s CFTR Potentiator CTP-656

Vertex Pharmaceuticals recently purchased the Phase 2 cystic fibrosis potentiator drug CTP-656 from Concert Pharmaceuticals. The deal is estimated to be worth $250 million dollars. CTP-656 is intended to be a longer-acting, once daily version of Vertex’s drug ivacaftor, which aims to restore CFTR function. The press release is here. …

READ MORE →
pollution chimney-324561_640
Living With CFResearchRespiratory Disease

Respiratory Health and Pollution

The impact of small particle air pollution on the lower airways (lungs) has long been studied, but now scientists have evidence of its negative impact on the upper sinonasal airways as well. The World Health Organization’s recommendation for small particle air pollution (PM2.5) is that it not exceed an average …

READ MORE →
pseudomonas2
GeneticsLiving With CFRespiratory DiseaseTreatments

Does Ivacaftor Affect Lung Bacteria in Cystic Fibrosis?

Ivacaftor has been shown to increase CFTR activity and lung function in people with Cystic Fibrosis and the G551D mutation, but until a recent study, scientists were not sure if ivacaftor changed the level of bacteria in the lungs. The results of a deeper study on ivacaftor have been published, …

READ MORE →
Exercise
ExerciseLiving With CFResearchRespiratory Disease

Research on CF and Exercise

Significant research, both recent and decades old, shows that exercise helps people with CF. Yet it’s not always a part of a person’s treatment regimen. Here are some facts that may convince you to exercise more with the the guidance and approval of your CF team. “Exercise can provide improvements …

READ MORE →
heart fibrosis
Living With CFResearchTreatments

Pulmozyme May Extend Lives of People Without Cystic Fibrosis

Pulmozyme might be able to extend the lives of people who don’t have CF according to a recent article in Science Daily, “Fighting age-related fibrosis to keep organs young.” Since it was approved by the FDA in 1993, Pulmozyme (dornase alpha or DNase) has been used by many people with …

READ MORE →
cftr2
DiagnosisGeneticsLiving With CF

New Guidelines for Cystic Fibrosis Diagnosis

New Guidelines for Cystic Fibrosis Diagnosis A group of 32 scientists from nine countries have updated the guidelines for Cystic Fibrosis diagnosis. They published an article last month in The Journal of Pediatrics and the synopsis can be found here in Science Daily. The scientists looked at data from people …

READ MORE →
DNA CRISPR
GeneticsLiving With CFResearchTechnology

Radio Interview: CRISPR Gene Editing

“There has never been a more powerful biological tool or one with more potential to both improve the world and endanger it.” For an in-depth look at the progress being made and the potential of CRISPR, the gene editing tool, listen to this radio interview on National Public Radio. Cystic …

READ MORE →
PGCFT
Living With CFNews & EventsResearchTechnology

Portable Genomics and CFTechnology.org Partnership

From PRNewswire Portable Genomics and CFTechnology.org have entered into a partnership to enable cystic fibrosis patients to better collect, manage and share important biometrics with caregivers, researchers and the pharmaceutical industry News provided by Portable Genomics Jan 17, 2017, 06:04 ET SAN DIEGO, Jan. 17, 2017 /PRNewswire/ — Portable Genomics …

READ MORE →
burkholderia
Living With CFResearchRespiratory Disease

CF Lung Microbiome: Diversity and Lung Function

The article, The Lung Microbiome and Airway Disease, published September 2016 in the Annals of the American Thoracic Society, describes various research studies that analyzed the relationship between the lung microbiome and airway disease. Scientists can now better examine microbial communities in the lungs, and they are looking at how …

READ MORE →
cigarette-666939_640
Living With CFResearchRespiratory DiseaseTreatments

CFTR Function and Cigarette Smoke

Scientists are looking at how the CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) potentiator, Ivacaftor, might be used in COPD, specifically chronic bronchitis. They found that cigarette smoking reduces CFTR activity in lung tissue, and that exposing the lung cells directly to a CFTR potentiator reverses this effect. While the vast …

READ MORE →